HealthModerna and Merck Revive mRNA Hopes With Melanoma Trial Success
A personalized vaccine developed by Moderna and Merck reduced melanoma recurrence in a large late-stage trial. The result raises expectations for treating the deadliest form of skin cancer and highlights the potential of embattled mRNA technology.
B
Bloomberg News★★★☆☆2026-08-19 16:30Original
Moderna and Merck Revive mRNA Hopes With Melanoma Trial Success
Health